Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round.
The proceeds will enable Memo to complete U.S. Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus infection in kidney renal transplant recipients.
The VISCHER team advising the lead investor in this transaction included partner Matthias Staehelin (pictured) and managing associate Vincent S. Reardon (both corporate/M&A) as well as senior associate Adrian Mangold (tax).